Clinical Trial Update: A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase II study of ABC294640 as monotherapy in advanced hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ABC294640

Snippet

Sponsor: Medical University of South Carolina | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: WITHDRAWN